A USA registry of gastrointestinal stromal tumor patients

Changes in practice over time and differences between community and academic practices

P. W T Pisters, Charles Blanke, M. von Mehren, J. Picus, A. Sirulnik, E. Stealey, J. C. Trent

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background: The objective of the study was to describe patterns of care of patients with gastrointestinal stromal tumors (GISTs) in the United States in the tyrosine kinase inhibitor (TKI) era. Patients and methods: From November 2004 through March 2009, data were collected regarding demographics, diagnostic history, treatment, relapse, and survival of 882 patients with GIST from 122 community and academic medical practices.Results: The most common first-line treatment for the 719 patients presenting with localized GIST was surgery (87%). Use of adjuvant imatinib increased after June 2007; 47% of patients enrolled in the registry considered by the investigator to be at high risk for recurrence received adjuvant imatinib after June 2007 versus 18% before. Overall, 56% of patients received imatinib and 11% received sunitinib. The utilization of targeted therapy increased over time (45% and 0.4% of patients received imatinib and sunitinib, respectively, in 2006 versus 56% and 11%, respectively, in 2009).Conclusions: These are the first GIST registry data from the TKI era. The use of targeted therapy for GIST has increased in accordance with updated treatment guidelines. Diagnosis of GIST has evolved with increased use of KIT testing. The duration of targeted therapy in the adjuvant therapy setting is similar in community and academic practices.

Original languageEnglish (US)
Pages (from-to)2523-2529
Number of pages7
JournalAnnals of Oncology
Volume22
Issue number11
DOIs
StatePublished - Nov 2011
Externally publishedYes

Fingerprint

Gastrointestinal Stromal Tumors
Registries
Protein-Tyrosine Kinases
Therapeutics
Recurrence
Patient Care
History
Research Personnel
Demography
Guidelines
Survival
Imatinib Mesylate

Keywords

  • Gastrointestinal stromal tumors
  • Registry
  • Survival
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

A USA registry of gastrointestinal stromal tumor patients : Changes in practice over time and differences between community and academic practices. / Pisters, P. W T; Blanke, Charles; von Mehren, M.; Picus, J.; Sirulnik, A.; Stealey, E.; Trent, J. C.

In: Annals of Oncology, Vol. 22, No. 11, 11.2011, p. 2523-2529.

Research output: Contribution to journalArticle

Pisters, P. W T ; Blanke, Charles ; von Mehren, M. ; Picus, J. ; Sirulnik, A. ; Stealey, E. ; Trent, J. C. / A USA registry of gastrointestinal stromal tumor patients : Changes in practice over time and differences between community and academic practices. In: Annals of Oncology. 2011 ; Vol. 22, No. 11. pp. 2523-2529.
@article{cffa513f3a17430a8901a7dcd9cfd78e,
title = "A USA registry of gastrointestinal stromal tumor patients: Changes in practice over time and differences between community and academic practices",
abstract = "Background: The objective of the study was to describe patterns of care of patients with gastrointestinal stromal tumors (GISTs) in the United States in the tyrosine kinase inhibitor (TKI) era. Patients and methods: From November 2004 through March 2009, data were collected regarding demographics, diagnostic history, treatment, relapse, and survival of 882 patients with GIST from 122 community and academic medical practices.Results: The most common first-line treatment for the 719 patients presenting with localized GIST was surgery (87{\%}). Use of adjuvant imatinib increased after June 2007; 47{\%} of patients enrolled in the registry considered by the investigator to be at high risk for recurrence received adjuvant imatinib after June 2007 versus 18{\%} before. Overall, 56{\%} of patients received imatinib and 11{\%} received sunitinib. The utilization of targeted therapy increased over time (45{\%} and 0.4{\%} of patients received imatinib and sunitinib, respectively, in 2006 versus 56{\%} and 11{\%}, respectively, in 2009).Conclusions: These are the first GIST registry data from the TKI era. The use of targeted therapy for GIST has increased in accordance with updated treatment guidelines. Diagnosis of GIST has evolved with increased use of KIT testing. The duration of targeted therapy in the adjuvant therapy setting is similar in community and academic practices.",
keywords = "Gastrointestinal stromal tumors, Registry, Survival, Tyrosine kinase inhibitor",
author = "Pisters, {P. W T} and Charles Blanke and {von Mehren}, M. and J. Picus and A. Sirulnik and E. Stealey and Trent, {J. C.}",
year = "2011",
month = "11",
doi = "10.1093/annonc/mdq773",
language = "English (US)",
volume = "22",
pages = "2523--2529",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - A USA registry of gastrointestinal stromal tumor patients

T2 - Changes in practice over time and differences between community and academic practices

AU - Pisters, P. W T

AU - Blanke, Charles

AU - von Mehren, M.

AU - Picus, J.

AU - Sirulnik, A.

AU - Stealey, E.

AU - Trent, J. C.

PY - 2011/11

Y1 - 2011/11

N2 - Background: The objective of the study was to describe patterns of care of patients with gastrointestinal stromal tumors (GISTs) in the United States in the tyrosine kinase inhibitor (TKI) era. Patients and methods: From November 2004 through March 2009, data were collected regarding demographics, diagnostic history, treatment, relapse, and survival of 882 patients with GIST from 122 community and academic medical practices.Results: The most common first-line treatment for the 719 patients presenting with localized GIST was surgery (87%). Use of adjuvant imatinib increased after June 2007; 47% of patients enrolled in the registry considered by the investigator to be at high risk for recurrence received adjuvant imatinib after June 2007 versus 18% before. Overall, 56% of patients received imatinib and 11% received sunitinib. The utilization of targeted therapy increased over time (45% and 0.4% of patients received imatinib and sunitinib, respectively, in 2006 versus 56% and 11%, respectively, in 2009).Conclusions: These are the first GIST registry data from the TKI era. The use of targeted therapy for GIST has increased in accordance with updated treatment guidelines. Diagnosis of GIST has evolved with increased use of KIT testing. The duration of targeted therapy in the adjuvant therapy setting is similar in community and academic practices.

AB - Background: The objective of the study was to describe patterns of care of patients with gastrointestinal stromal tumors (GISTs) in the United States in the tyrosine kinase inhibitor (TKI) era. Patients and methods: From November 2004 through March 2009, data were collected regarding demographics, diagnostic history, treatment, relapse, and survival of 882 patients with GIST from 122 community and academic medical practices.Results: The most common first-line treatment for the 719 patients presenting with localized GIST was surgery (87%). Use of adjuvant imatinib increased after June 2007; 47% of patients enrolled in the registry considered by the investigator to be at high risk for recurrence received adjuvant imatinib after June 2007 versus 18% before. Overall, 56% of patients received imatinib and 11% received sunitinib. The utilization of targeted therapy increased over time (45% and 0.4% of patients received imatinib and sunitinib, respectively, in 2006 versus 56% and 11%, respectively, in 2009).Conclusions: These are the first GIST registry data from the TKI era. The use of targeted therapy for GIST has increased in accordance with updated treatment guidelines. Diagnosis of GIST has evolved with increased use of KIT testing. The duration of targeted therapy in the adjuvant therapy setting is similar in community and academic practices.

KW - Gastrointestinal stromal tumors

KW - Registry

KW - Survival

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=80355143677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80355143677&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdq773

DO - 10.1093/annonc/mdq773

M3 - Article

VL - 22

SP - 2523

EP - 2529

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 11

ER -